Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients

Molecular Oncology

Volumn 10, Issue 3, 2016, Pages 450-463

  Huang, Sharon K ^a   Hoon, Dave S B ^a  

^a SAINT JOHN'S HEALTH CENTER   (United States)

Author keywords

Cell free circulating tumor DNA; Cell free DNA; Cell free microRNA; Circulating tumor cells; Liquid biopsy; Melanoma

Indexed keywords

CELL FREE CIRCULATING MICRORNA; CELL FREE CIRCULATING TUMOR DNA; DNA; MICRORNA; UNCLASSIFIED DRUG; B RAF KINASE; BRAF PROTEIN, HUMAN;

CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CIRCULATING TUMOR CELL; COPY NUMBER VARIATION; CUTANEOUS MELANOMA; DISTANT METASTASIS; DNA METHYLATION; HETEROZYGOSITY LOSS; HUMAN; LIQUID BIOPSY; MICROSATELLITE INSTABILITY; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SKIN BIOPSY; BIOPSY; BLOOD; GENETICS; MELANOMA; METABOLISM; MUTATION; PATHOLOGY; PROGNOSIS; SKIN; SKIN NEOPLASMS; TUMOR EMBOLISM;

BIOPSY; DNA, NEOPLASM; HUMANS; MELANOMA; MICRORNAS; MUTATION; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN; SKIN NEOPLASMS;

EID: 84959149356     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.12.008     Document Type: Review

References (74)

1. Ambros V. MicroRNAs: tiny regulators with great potential. Cell 2001, 107:823-826.
2. Asaga S., Kuo C., Nguyen T., Terpenning M., Giuliano A.E., Hoon D.S. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 2011, 57:84-91.
3. Austin L.K., Fortina P., Sebisanovic D., Siew L., Zapanta A., Talasaz A., Cristofanilli M. Circulating tumor DNA (ctDNA) as a molecular monitoring tool in metastatic breast cancer (MBC). ASCO Meet. Abstr. 2014, 32:11093.
4. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., Buzaid A.C., Cochran A.J., Coit D.G., Ding S., Eggermont A.M., Flaherty K.T., Gimotty P.A., Kirkwood J.M., McMasters K.M., Mihm M.C., Morton D.L., Ross M.I., Sober A.J., Sondak V.K. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009, 27:6199-6206.
5. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
6. Bertoli G., Cava C., Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics 2015, 5:1122-1143.
7. Chan K.C., Jiang P., Zheng Y.W., Liao G.J., Sun H., Wong J., Siu S.S., Chan W.C., Chan S.L., Chan A.T., Lai P.B., Chiu R.W., Lo Y.M. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 2013, 59:211-224.
8. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S.J., Sosman J.A., Kirkwood J.M., Eggermont A.M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R.J., Flaherty K.T., McArthur G.A., Group B.-S. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl. J. Med. 2011, 364:2507-2516.
9. Chiu C.G., Nakamura Y., Chong K.K., Huang S.K., Kawas N.P., Triche T., Elashoff D., Kiyohara E., Irie R.F., Morton D.L., Hoon D.S. Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin. Chem. 2014, 60:873-885.
10. Daniotti M., Vallacchi V., Rivoltini L., Patuzzo R., Santinami M., Arienti F., Cutolo G., Pierotti M.A., Parmiani G., Rodolfo M. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int. J. Cancer J. Int. du Cancer 2007, 120:2439-2444.
11. Edge S., Compton C., Fritz A., Greene F., Trotti A. Melanoma of the Skin 2010, 648. Springer, New York. S. Edge (Ed.).
12. Fleming N.H., Zhong J., da Silva I.P., Vega-Saenz de Miera E., Brady B., Han S.W., Hanniford D., Wang J., Shapiro R.L., Hernando E., Osman I. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer 2015, 121:51-59.
13. Friedman E.B., Shang S., de Miera E.V., Fog J.U., Teilum M.W., Ma M.W., Berman R.S., Shapiro R.L., Pavlick A.C., Hernando E., Baker A., Shao Y., Osman I. Serum microRNAs as biomarkers for recurrence in melanoma. J. Transl. Med. 2012, 10:155.
14. Fujimoto A., O'Day S.J., Taback B., Elashoff D., Hoon D.S. Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res. 2004, 64:4085-4088.
15. Fujimoto A., Takeuchi H., Taback B., Hsueh E.C., Elashoff D., Morton D.L., Hoon D.S. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res. 2004, 64:2245-2250.
16. Fujiwara Y., Chi D.D., Wang H., Keleman P., Morton D.L., Turner R., Hoon D.S. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res. 1999, 59:1567-1571.
17. Fusi A., Collette S., Busse A., Suciu S., Rietz A., Santinami M., Kruit W.H., Testori A., Punt C.J., Dalgleish A.G., Spatz A., Eggermont A.M., Keilholz U. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur. J. Cancer 2009, 45:3189-3197.
18. Girotti M.R., Saturno G., Lorigan P., Marais R. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. Mol. Oncol. 2014, 8:1140-1158.
19. Goto Y., Koyanagi K., Narita N., Kawakami Y., Takata M., Uchiyama A., Nguyen L., Nguyen T., Ye X., Morton D.L., Hoon D.S. Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. J. Invest. Dermatol. 2010, 130:221-229.
20. Gray E.S., Reid A.L., Bowyer S., Calapre L., Siew K., Pearce R., Cowell L., Frank M.H., Millward M., Ziman M. Circulating melanoma cell subpopulations: their heterogeneity and differential responses to treatment. J. Invest. Dermatol. 2015, 135:2040-2048.
21. Greenberg E., Besser M.J., Ben-Ami E., Shapira-Frommer R., Itzhaki O., Zikich D., Levy D., Kubi A., Eyal E., Onn A., Cohen Y., Barshack I., Schachter J., Markel G. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers 2013, 18:502-508.
22. Heitzer E., Ulz P., Geigl J.B. Circulating tumor DNA as a liquid biopsy for cancer. Clin. Chem. 2015, 61:112-123.
23. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl. J. Med. 2010, 363:711-723.
24. Hoon D.S., Spugnardi M., Kuo C., Huang S.K., Morton D.L., Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004, 23:4014-4022.
25. Hoon D.S.B., Huang S., Sebisanovic D., Siew L., Zapanta A., Mortimer S., Talasaz A. Identification of multiple informative genomic mutations by deep sequencing of circulating cell-free tumor DNA in plasma of metastatic melanoma patients. ASCO Meet. Abstr. 2014, 32:9018.
26. Hoshimoto S., Faries M.B., Morton D.L., Shingai T., Kuo C., Wang H.J., Elashoff R., Mozzillo N., Kelley M.C., Thompson J.F., Lee J.E., Hoon D.S. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann. Surg. 2012, 255:357-362.
27. Hoshimoto S., Kuo C.T., Chong K.K., Takeshima T.L., Takei Y., Li M.W., Huang S.K., Sim M.S., Morton D.L., Hoon D.S. AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J. Invest. Dermatol. 2012, 132:1689-1697.
28. Hoshimoto S., Shingai T., Morton D.L., Kuo C., Faries M.B., Chong K., Elashoff D., Wang H.J., Elashoff R.M., Hoon D.S. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J. Clin. Oncol. 2012, 30:3819-3826.
29. Jarry J., Schadendorf D., Greenwood C., Spatz A., van Kempen L.C. The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol. Oncol. 2014, 8:819-829.
30. Kanemaru H., Fukushima S., Yamashita J., Honda N., Oyama R., Kakimoto A., Masuguchi S., Ishihara T., Inoue Y., Jinnin M., Ihn H. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J. Dermatol. Sci. 2011, 61:187-193.
31. Khoja L., Lorigan P., Dive C., Keilholz U., Fusi A. Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. Ann. Oncol. 2015, 26:33-39.
32. Khoja L., Lorigan P., Zhou C., Lancashire M., Booth J., Cummings J., Califano R., Clack G., Hughes A., Dive C. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J. Invest. Dermatol. 2013, 133:1582-1590.
33. Kim V.N. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 2005, 6:376-385.
34. Kitago M., Koyanagi K., Nakamura T., Goto Y., Faries M., O'Day S.J., Morton D.L., Ferrone S., Hoon D.S. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin. Chem. 2009, 55:757-764.
35. Koyanagi K., Kuo C., Nakagawa T., Mori T., Ueno H., Lorico A.R., Wang H.J., Hseuh E., O'Day S.J., Hoon D.S. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin. Chem. 2005, 51:981-988.
36. Koyanagi K., Mori T., O'Day S.J., Martinez S.R., Wang H.J., Hoon D.S. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res. 2006, 66:6111-6117.
37. Koyanagi K., O'Day S.J., Boasberg P., Atkins M.B., Wang H.J., Gonzalez R., Lewis K., Thompson J.A., Anderson C.M., Lutzky J., Amatruda T.T., Hersh E., Richards J., Weber J.S., Hoon D.S. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin. Cancer Res. 2010, 16:2402-2408.
38. Koyanagi K., O'Day S.J., Gonzalez R., Lewis K., Robinson W.A., Amatruda T.T., Wang H.J., Elashoff R.M., Takeuchi H., Umetani N., Hoon D.S. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J. Clin. Oncol. 2005, 23:8057-8064.
39. Kuhlmann J.D., Schwarzenbach H., Wimberger P., Poetsch M., Kimmig R., Kasimir-Bauer S. LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. BMC Cancer 2012, 12:325.
40. Lanman R.B., Mortimer S.A., Zill O.A., Sebisanovic D., Lopez R., Blau S., Collisson E.A., Divers S.G., Hoon D.S., Kopetz E.S., Lee J., Nikolinakos P.G., Baca A.M., Kermani B.G., Eltoukhy H., Talasaz A. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One 2015, 10:e0140712.
41. Lim C., Hoon D. Circulating tumor cells: cancer's deadly couriers. Phys. Today 2014, 67:26-30.
42. Lo Nigro C., Wang H., McHugh A., Lattanzio L., Matin R., Harwood C., Syed N., Hatzimichael E., Briasoulis E., Merlano M., Evans A., Thompson A., Leigh I., Fleming C., Inman G.J., Proby C., Crook T. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J. Invest. Dermatol. 2013, 133:1278-1285.
43. Luo X., Mitra D., Sullivan R.J., Wittner B.S., Kimura A.M., Pan S., Hoang M.P., Brannigan B.W., Lawrence D.P., Flaherty K.T., Sequist L.V., McMahon M., Bosenberg M.W., Stott S.L., Ting D.T., Ramaswamy S., Toner M., Fisher D.E., Maheswaran S., Haber D.A. Isolation and molecular characterization of circulating melanoma cells. Cell Rep. 2014, 7:645-653.
44. Margue C., Reinsbach S., Philippidou D., Beaume N., Walters C., Schneider J.G., Nashan D., Behrmann I., Kreis S. Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer?. Oncotarget 2015, 6:12110-12127.
45. Marzese D.M., Hirose H., Hoon D.S. Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev. Mol. Diagn. 2013, 13:827-844.
46. Miyashiro I., Kuo C., Huynh K., Iida A., Morton D., Bilchik A., Giuliano A., Hoon D.S. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin. Chem. 2001, 47:505-512.
47. Mori T., Martinez S.R., O'Day S.J., Morton D.L., Umetani N., Kitago M., Tanemura A., Nguyen S.L., Tran A.N., Wang H.J., Hoon D.S. Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res. 2006, 66:6692-6698.
48. Mori T., O'Day S.J., Umetani N., Martinez S.R., Kitago M., Koyanagi K., Kuo C., Takeshima T.L., Milford R., Wang H.J., Vu V.D., Nguyen S.L., Hoon D.S. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J. Clin. Oncol. 2005, 23:9351-9358.
49. Ono S., Lam S., Nagahara M., Hoon D.S. Circulating microRNA biomarkers as liquid biopsy for cancer patients: pros and cons of current assays. J. Clin. Med. 2015, 4:1890-1907.
50. Ono S., Oyama T., Lam S., Chong K., Foshag L.J., Hoon D.S. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget 2015, 6:7053-7064.
51. Pinzani P., Salvianti F., Zaccara S., Massi D., De Giorgi V., Pazzagli M., Orlando C. Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin. Chim. Acta Int. J. Clin. Chem. 2011, 412:2141-2145.
52. Quaglino P., Osella-Abate S., Cappello N., Ortoncelli M., Nardo T., Fierro M.T., Cavallo F., Savoia P., Bernengo M.G. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Res. 2007, 17:75-82.
53. Ramskold D., Luo S., Wang Y.C., Li R., Deng Q., Faridani O.R., Daniels G.A., Khrebtukova I., Loring J.F., Laurent L.C., Schroth G.P., Sandberg R. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat. Biotechnol. 2012, 30:777-782.
54. Reid A.L., Freeman J.B., Millward M., Ziman M., Gray E.S. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clin. Biochem. 2015, 48:999-1002.
55. Rodic S., Mihalcioiu C., Saleh R.R. Detection methods of circulating tumor cells in cutaneous melanoma: a systematic review. Crit. Rev. Oncol. Hematol. 2014, 91:74-92.
56. Saldanha G., Potter L., Shendge P., Osborne J., Nicholson S., Yii N., Varma S., Aslam M.I., Elshaw S., Papadogeorgakis E., Pringle J.H. Plasma microRNA-21 is associated with tumor burden in cutaneous melanoma. J. Invest. Dermatol. 2013, 133:1381-1384.
57. Salvianti F., Pinzani P., Verderio P., Ciniselli C.M., Massi D., De Giorgi V., Grazzini M., Pazzagli M., Orlando C. Multiparametric analysis of cell-free DNA in melanoma patients. PLoS One 2012, 7:e49843.
58. Santiago-Walker A., Gagnon R., Mazumdar J., Casey M., Long G.V., Schadendorf D., Flaherty K., Kefford R., Hauschild A., Hwu P., Haney P., O'Hagan A., Carver J., Goodman V., Legos J., Martin A.M. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin. Cancer Res. 2015 Oct 7, 1-8. [Epub ahead of print].
59. Schwarzenbach H., da Silva A.M., Calin G., Pantel K. Data normalization strategies for microRNA quantification. Clin. Chem. 2015, 61:1333-1342.
60. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
61. Schwarzenbach H., Nishida N., Calin G.A., Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol. 2014, 11:145-156.
62. Scoggins C.R., Ross M.I., Reintgen D.S., Noyes R.D., Goydos J.S., Beitsch P.D., Urist M.M., Ariyan S., Davidson B.S., Sussman J.J., Edwards M.J., Martin R.C., Lewis A.M., Stromberg A.J., Conrad A.J., Hagendoorn L., Albrecht J., McMasters K.M. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J. Clin. Oncol. 2006, 24:2849-2857.
63. Shiiyama R., Fukushima S., Jinnin M., Yamashita J., Miyashita A., Nakahara S., Kogi A., Aoi J., Masuguchi S., Inoue Y., Ihn H. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res. 2013, 23:366-372.
64. Shinozaki M., O'Day S.J., Kitago M., Amersi F., Kuo C., Kim J., Wang H.J., Hoon D.S. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin. Cancer Res. 2007, 13:2068-2074.
65. Smith B., Selby P., Southgate J., Pittman K., Bradley C., Blair G.E. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991, 338:1227-1229.
66. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., Hersey P., Kefford R., Lawrence D., Puzanov I., Lewis K.D., Amaravadi R.K., Chmielowski B., Lawrence H.J., Shyr Y., Ye F., Li J., Nolop K.B., Lee R.J., Joe A.K., Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. New Engl. J. Med. 2012, 366:707-714.
67. Stark M.S., Klein K., Weide B., Haydu L.E., Pflugfelder A., Tang Y.H., Palmer J.M., Whiteman D.C., Scolyer R.A., Mann G.J., Thompson J.F., Long G.V., Barbour A.P., Soyer H.P., Garbe C., Herington A., Pollock P.M., Hayward N.K. The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: a microRNA expression analysis. EBioMedicine 2015, 2:671-680.
68. Taback B., Fujiwara Y., Wang H.J., Foshag L.J., Morton D.L., Hoon D.S. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res. 2001, 61:5723-5726.
69. Taback B., Giuliano A.E., Hansen N.M., Singer F.R., Shu S., Hoon D.S. Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients. Cancer Res. 2003, 63:1884-1887.
70. Taback B., O'Day S.J., Boasberg P.D., Shu S., Fournier P., Elashoff R., Wang H.J., Hoon D.S. Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J. Natl. Cancer Inst. 2004, 96:152-156.
71. Tsao S.C., Weiss J., Hudson C., Christophi C., Cebon J., Behren A., Dobrovic A. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci. Rep. 2015, 5:11198.
72. Umetani N. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin. Chem. 2006, 52:1062-1069.
73. Umetani N. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J. Clin. Oncol. 2006, 24:4270-4276.
74. Zhang Z., Irie R.F., Chi D.D., Hoon D.S. Cellular immuno-PCR. Detection of a carbohydrate tumor marker. Am. J. Pathol. 1998, 152:1427-1432.